Renal Artery Denervation as a Novel Approach to Treating Resistant Hypertension
A Comprehensive Literature Review
DOI:
https://doi.org/10.12775/QS.2025.41.60015Keywords
renal artery denervation, resistant hypertension, sympathetic nervous systemAbstract
Resistant hypertension is a condition in which blood pressure remains uncontrolled despite the use of at least three antihypertensive drugs—one of which must be a diuretic—at maximum tolerated doses and in an appropriate combination. In Poland, it is estimated that the percentage of patients with this condition may reach 10–13% of the general population of individuals with hypertension. These patients have a higher risk of complications, such as strokes or cardiovascular diseases, compared to patients with controlled hypertension. A thorough medical history, physical examination, and laboratory tests form the foundation of diagnosis, which must be approached from multiple angles to exclude pseudo-resistant hypertension or secondary causes. The sympathetic nervous system plays an important role in the pathophysiology of resistant hypertension: its increased activity contributes to persistently high blood pressure values. First-line treatment includes lifestyle modifications and combination drug therapy. When pharmacological therapy fails to bring the expected results, an innovative procedure—renal artery denervation—may be considered. By ablating the afferent and efferent fibers of the sympathetic nervous system, sympathetic tone is reduced, leading to a reduction in blood pressure. Patient selection involves a series of specialized tests. The previously conducted Symplicity HTN-1 and Symplicity HTN-2 studies show a significant reduction in blood pressure after the denervation procedure. Ongoing studies aim to gather more information on the effects and outcomes of renal artery denervation.
References
1. World Health Organization. A global brief on Hypertension, World Health Organization, 2013.
2. Aleksandra Baszczuk, Zygmunt Kopczyński, Katarzyna Musialik. “Rozpowszechnienie nadciśnienia tętniczego na świecie i w Polsce.” Forum Zaburzeń Metabolicznych 2014, vol. 5, no. 4, pp. 141–147.
3. Klaudia Suligowska, Małgorzata Gajewska, Jakub Stokwiszewski, Zbigniew Gaciong, Piotr Bandosz, Bogdan Wojtyniak, Marcin Rutkowski, Dorota Cianciara, Bogdan Wyrzykowski, Tomasz Zdrojewski. “Niedostateczna wiedza Polaków na temat kryteriów nadciśnienia tętniczego i jego powikłań — wyniki badania NATPOL 2011.” Nadciśnienie Tętnicze 2014, vol. 18, no. 1, pp. 9–18.
4. Tykarski, Krzysztof J. Filipiak, Andrzej Januszewicz, Mieczysław Litwin, Krzysztof Narkiewicz, Aleksander Prejbisz, Danuta Ostalska-Nowicka, Krystyna Widecka, Katarzyna Kostka-Jeziorny. “Zasady postępowania w nadciśnieniu tętniczym — 2019 rok.” Nadciśnienie Tętnicze w Praktyce 2019, vol. 5, no. 1, pp. 1–86.
5. Calhoun D.A., Jones D., Textor S. et al. “Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.” Hypertension 2008; 51: 1403–1419.
6. Januszewicz A., Prejbisz A. Oporne nadciśnienie tętnicze. Zasady postępowania w praktyce lekarskiej. Via Medica, Gdańsk 2009.
7. Tsioufis C, Kordalis A, Flessas D. “Pathophysiology of resistant hypertension: the role of sympathetic nervous system.” Int J Hypertens 2011, 642416.
8. Mancia G., Laurent S., Agabiti-Rosei E. et al. “Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.” J. Hypertens. 2009; 27: 2121–2158.
9. Desir G.V. “Regulation of blood pressure and cardiovascular function by renalase.” Kidney Int. 2009, 76, 366.
10. Katholl R.E., Rocha-Singh K.J. “The role of sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance?” Prog. Cardiovasc. Dis. 2009, 52, 243.
11. Krum H, Schlaich M, Whitbourn R. “Catheter-based renal sympathetic denervation for resistant hypertension. A multicentre safety and proof-of-principle cohort study.” Lancet 2009, 373, 1275–1281.
12. Guidelines Committee. “2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension.” J Hypertens 2003, 21, 1011–1153.
13. Tykarski A. “Nadciśnienie tętnicze oporne.” Choroby Serca Naczyń 2005, 2, 190–193.
14. Bunker J., Callister W., Chang C.L., Sever P.S. “How common is true resistant hypertension?” J. Hum. Hypertens. 2011; 25: 137–140.
15. Zieleń P., Januszewicz W., Januszewicz A. “Oporne nadciśnienie tętnicze.” Nadciśnienie Tętnicze 2009, vol. 13, no. 3, pp. 206–214.
16. Januszewicz W., Dworzański W., Prejbisz A., Januszewicz A. “Nadciśnienie tętnicze oporne — wybrane częste i rzadkie przyczyny, o których należy pamiętać w praktyce klinicznej.” Choroby Serca i Naczyń 2012, vol. 9, no. 2, pp. 85–89.
17. Januszewicz A., Prejbisz A. Oporne nadciśnienie tętnicze. Zasady postępowania w praktyce lekarskiej. Via Medica, Gdańsk 2009.
18. Pickering T.G. “Blood pressure monitoring outside the office for evaluation of patients with resistant hypertension.” Hypertension 1988; 11 (suppl. II): 96–100.
19. Veglio F., Rabbia F., Riva P. et al. “Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension.” Clin. Exp. Hypertens. 2001; 23: 203–211.
20. Mann JS. “Drug therapy for resistant hypertension: a simplified, mechanistic approach.” J Clin Hypertens 2011, 13, 120–130.
21. Doroszko A., Janus A., Szahidewicz-Krupska E., Mazur G., Derkacz A. “Resistant Hypertension.” Adv Clin Exp Med 2016, 25, 1, 173–183.
22. Januszewicz W., Januszewicz A., Prejbisz A. “Udział aldosteronu w patogenezie nadciśnienia tętniczego — implikacje praktyczne.” Terapia 2008; 7–8: 23–26.
23. Eide I.K., Torjesen P.A., Drolsun A. et al. “Low-renin status in therapy–resistant hypertension: a clue to efficient treatment.” J. Hypertens. 2004; 22: 2217–2226.
24. Witkowski A., Januszewicz A., Imiela J. et al. “Stanowisko grupy ekspertów w sprawie zabiegów przezskórnej denerwacji nerek w leczeniu nadciśnienia tętniczego w Polsce.” Kardiol. Pol. 2011; 69: 1208–1211.
25. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. “Guideline Development Group. Management of hypertension: summary of NICE guidance.” BMJ 2011, 25, 343:d4891.
26. Gawron-Klszka M., Żukowska-Szczechowska E., Tomaszewski M. “Postępy w genetyce nadciśnienia tętniczego.” Post. Nefrol. Nadciśn. Tętn. 2009, 8,11.
27. Januszewicz A., Prejbisza. “Nadciśnienie tętnicze.” In: Choroby wewnętrzne - stan wiedzy na rok 2011. Ed. A. Szczeklik, Med. Prakt. 2011, 391.
28. Kostka-Jeziorny K., Kądziela J., Grajek S., Tykarski A. “Denerwacja tętnic nerkowych — nowa inwazyjna metoda leczenia nadciśnienia tętniczego opornego.” Nadciśnienie Tętnicze 2012, vol. 16, no. 1, pp. 1–8.
29. Schlaich i wsp. Hypertension 2009; 54: 1195–1201.
30. Grassl G., Bertolt S., Seravalle G. “Sympathetic nervous system: role in hypertension and chronic kidney disease.” Curr. Opin. Nephrol. Hypertens. 2012, 21, 46.
31. Esler M., Jennings G., Lambert G. “Noradrenaline release and the pathophysiology of primary human hypertension.” Am. J. Hypertens. 1989; 2: 140–146.
32. Schlaich M.P., Sobotka P.A., Krum H. et al. “Renal sympathetic-nerve ablation for uncontrolled hypertension.” N. Engl. J. Med. 2009; 361: 932–934.
33. Simplicity HTN-2 Investigators, Ester M.D., Krum H. et al. “Renal sympathetic denervation in patients with treatment resistant hypertension (The Simplicity HTN-2 Trial): a randomized controlled trial.” Lancet 2010, 376, 1903–1909.
34. Kazmirowicz M. “Metody interwencyjne w leczeniu opornego nadciśnienia tętniczego. Denerwacja tętnic nerkowych.” Nadciśnienie Tętnicze 2013, vol. 17, no. 3, pp. 191–201.
35. Rocha-Singh K.J. “Renal artery denervation; a brave new frontier.” Endovascular Today 2012; 1: 1–9.
36. Kądziela J., Florczak E., Januszewicz A., Witkowski A. “Denerwacja nerek — nowa metoda leczenia opornego nadciśnienia tętniczego.” Post. Kardiol. Interw. 2010; 6: 173–176.
37. Szwench E., Florczak E., Prejbisz A., Kądziela J., Witkowski A., Januszewicz A. “Oporne nadciśnienie tętnicze — postępy w diagnostyce i leczeniu.” Kardiologia Polska 2012; 70, 1: 66–74.
38. Symplicity HTN-1 Investigators. “Catheter-based renal sympathetic denervation for resistant hypertension durability of blood pressure reduction out to 24 months.” Hypertension 2011; 57: 911–917.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aneta Rasińska, Piotr Rzyczniok, Anna Rzyczniok, Weronika Rasińska, Justyna Jachimczak, Justyna Matusik, Paulina Bala, Aneta Rostkowska, Sebastian Kupisiak, Natalia Pasierb, Mateusz Kopczyński
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 123
Number of citations: 0
